Compare Tidewater Inc (TDW) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tidewater Inc vs Viatris Inc — how do they compare? Tidewater Inc trades at $91.74 (market cap $4.54B), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Viatris Inc is far larger — about 4.1× Tidewater Inc's market cap, and Viatris Inc pays a 2.95% dividend while Tidewater Inc pays none. Which is the better fit depends on your goals.
| TDW | VTRS | |
|---|---|---|
Market Cap | $4.54B | $18.69B |
Sector | Utilities | Health |
52-Week High | $91.20 | $17.86 |
52-Week Low | $47.29 | $9.49 |
Enterprise Value | $4.58B | $30.80B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tidewater (TDW) trades at $91.61, up 2.21% with strong technical momentum and bullish moving average signals. The company reported Q2 2026 earnings of $0.43 per share, beating estimates, with revenue of $342.3 million. Despite recent earnings misses, operational cash flow remains robust at $379 million for 2025, though 2026 projections show declining revenue and margins. Analyst sentiment is mixed with 26.9% buy ratings amid elevated RSI levels suggesting potential overbought conditions.
The stock faces headwinds from declining profitability trends and earnings volatility, but strong institutional ownership and positive technical indicators support near-term upside. Key risks include execution challenges and macroeconomic pressures on the offshore services sector. Investors should weigh solid cash generation against margin compression for balanced positioning.
Viatris (VTRS) trades at $16.105, down 1.07% on the day, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings beat estimates with EPS of $0.69 and revenue growth of 5%, but the company posted a net loss of $3.51B in 2025. Positive developments include FDA approval for Gwyn Lo and a raised 2026 outlook, though debt remains elevated at $14.04B long-term.
Outlook is cautious; while operational cash flow is strong at $2.32B and dividends provide income, persistent net losses and high P/E of 236.2 signal overvaluation risks. Analyst consensus leans Hold (61.54%), with upside potential if turnaround gains traction, but investors face headwinds from generic drug pricing pressures and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
